{"id":"W2586189263","doi":"10.1093/annonc/mdw371.105","title":"Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Placebo; Hepatocellular carcinoma; Randomized controlled trial; Oncology; Milan criteria; Transplantation; Cancer; Surgery; Clinical trial; Liver transplantation; Phases of clinical research; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001306035,0.00135028,0.002573682,0.0003147451,0.0004042082,0.001177384,0.0007625042,0.001123714,0.007232661],"category_scores_gemma":[0.001285516,0.0005857697,0.001994761,0.0003617709,0.0008512918,0.001286388,0.0004000324,0.003372348,0.001223291],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009205373,"about_ca_system_score_gemma":0.0009468392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001125428,"about_ca_topic_score_gemma":0.002673344,"domain_scores_codex":[0.9996897,0.0001431958,0.00001435417,0.00006371051,0.00002448613,0.00006470455],"domain_scores_gemma":[0.9993825,0.0001758129,0.0001383695,0.0000577871,0.00003333186,0.0002122357],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9681135,0.005027535,0.0005384196,0.0007918669,0.001833899,0.00003428031,0.00004428463,0.0005474556,0.00229479,0.0001417164,0.001478974,0.01915319],"study_design_scores_gemma":[0.9508637,0.04504706,0.00154083,0.00004674388,0.0009134237,0.00003346808,0.00002547793,0.0003370713,0.0002838862,0.0002007461,0.0006946888,0.0000129808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814199,0.007598255,0.001065257,0.0012867,0.0007297491,0.00245137,0.001770199,0.0001754726,0.003503141],"genre_scores_gemma":[0.9832562,0.004340889,0.001533836,0.001754369,0.0004231138,0.002496179,0.001329266,0.00004190882,0.004824303],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007232661,"threshold_uncertainty_score":0.02419567,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1131232089151935,"score_gpt":0.3784021611375279,"score_spread":0.2652789522223344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}